Simultaneous electrical recording of cardiac electrophysiology and contraction on chip

Qian, Fang; Huang, Chao; Lin, Yi; Ivanovskaya, Anna; O’Hara, Thomas; Booth, R.; Creek, Cameron J.; Enright, Heather A.; Soscia, David A.; Belle, Anna M.; Liao, Ronglih; Lightstone, Felice C.; Kulp, Kristen S.; Wheeler, Elizabeth K.

doi:10.1039/c7lc00210f

Cited by 112 publications

(94 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Norepinephrine exerts its effect by activating β1 receptors enhancing the contraction of cardiomyocytes while the signal amplitude remains unchanged, see the Supporting Information. Notably, given the different protein expression from cell to cell and the drug injection location, the time‐dependent traces (Figure S10, Supporting Information) and real‐time map reveal a remarkable change of the action potential propagation after administration of norepinephrine. The initial activation spot of action potential shifted from OECT 10 (6, 5) (Figure b) to OECT 1 (2, 6) (Figure c), accompanied by a reversed propagation direction.…”

Section: Resultsmentioning

confidence: 99%

High Performance Flexible Organic Electrochemical Transistors for Monitoring Cardiac Action Potential

Liang

Ernst

Brings

et al. 2018

Adv Healthcare Materials

View full text Add to dashboard Cite

Flexible and transparent electronic devices possess crucial advantages over conventional silicon based systems for bioelectronic applications since they are able to adapt to nonplanar surfaces, cause less chronic immunoreactivity, and facilitate easy optical inspection. Here, organic electrochemical transistors (OECTs) are embedded in a flexible matrix of polyimide to record cardiac action potentials. The wafer-scale fabricated devices exhibit transconductances (12 mS V ) and drain-source on-to-off current ratios (≈10 ) comparable to state of the art nonflexible and superior to other reported flexible OECTs. The transfer characteristics of the devices are preserved even after experiencing extremely high bending strain and harsh crumpling. A sub-micrometer poly(3,4-ethylenedioxythiophene) doped with poly(styrenesulfonate) layer results in a fast transport of ions between the electrolyte and the polymer channel characterized by a cut-off frequency of 1200 Hz. Excellent device performance is proved by mapping the propagation of cardiac action potentials with high signal-to-noise ratio. These results demonstrate that the electrical performance of flexible OECTs can compete with hard-material-based OECTs and thus potentially be used for in vivo applications.

show abstract

Section: Resultsmentioning

confidence: 99%

High Performance Flexible Organic Electrochemical Transistors for Monitoring Cardiac Action Potential

Liang

Ernst

Brings

et al. 2018

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Yang Jianmin et al [91] reported the first microfluidic devices to achieve cardiac myocytes (CMs) anisotropy ( Figure 3A). Qian et al [92] constructed a cardiac chip that consists of a microelectrode array (MEA) for potential field indication and an interleaved electrode array for conversion. The platform uses transplantation of cardiomyocytes (CMs) derived from human induced pluripotent stem cells (hiPSC-CMs) to measure the electrophysiology and contractility of myocardial cells under physiological conditions and drug stimulation, respectively.…”

Section: Heart-on-a-chip For Drug-induced Cardiotoxicity Testingmentioning

confidence: 99%

Drug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review

et al. 2020

View full text Add to dashboard Cite

Organ-on-a-chip academic research is in its blossom. Drug toxicity evaluation is a promising area in which organ-on-a-chip technology can apply. A unique advantage of organ-on-a-chip is the ability to integrate drug metabolism and drug toxic processes in a single device, which facilitates evaluation of toxicity of drug metabolites. Human organ-on-a-chip has been fabricated and used to assess drug toxicity with data correlation with the clinical trial. In this review, we introduced the microfluidic chip models of liver, kidney, heart, nerve, and other organs and multiple organs, highlighting the application of these models in drug toxicity detection. Some biomarkers of toxic injury that have been used in organ chip platforms or have potential for use on organ chip platforms are summarized. Finally, we discussed the goals and future directions for drug toxicity evaluation based on organ-on-a-chip technology.

show abstract

“…For a more thorough review of currently available OOCs, refer to these reviews (An et al, 2015;Esch et al, 2015;Balijepalli and Sivaramakrishan, 2017;Low and Tagle, 2017;Kimura et al, 2018). Although they each started with simplistic models, each of these platforms has now been advanced to adapt novel physiologically relevant functions such as cellular contractions (i.e., heart, lung, and eye) (Huh, 2015;Qian et al, 2017;Seo et al, 2019), drug synthesis and excretion (i.e., liver and kidney) (Paoli and Samitier, 2016;Deng et al, 2019), barrier functions (i.e., skin and brain) (Jeong et al, 2018;Mieremet et al, 2019), dynamic flow of blood, air, or fluid interfaces (i.e., heart, lung) (Ribas et al, 2016;Artzy-Schnirman et al, 2019), and even co-culture with bacterial microbiomes (i.e., intestine) (Jalili-Firoozinezhad et al, 2019) in order to replicate the human organ systems of interest. In addition, multiple organ chips can be integrated, either physically through tubing or microfluidic channels or virtually by sending effluents from one OOC to another OOC, to create in vitro models of interconnected organ systems, with the ultimate goal of mimicking the entire human physiology (Maschmeyer et al, 2015;Materne et al, 2015;Kimura et al, 2018;Ramme et al, 2019).…”

Section: Introductionmentioning

confidence: 99%